Business Wire

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its ...
Morningstar

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune ...
IEEE

Model-Driven Architecture for Accelerating the Development of Tourism Applications

Abstract: The tourism sector has witnessed a significant shift towards digital transformation, with mobile and web applications becoming essential tools for enhancing tourist experiences. Despite ...
IEEE

Enhancing Test-Driven Development for Reconfigurable Hardware through High-Level Synthesis and Early-Stage Validation

Abstract: High-level synthesis tools help engineers deal with the challenges of building complex systems that use reconfigurable technologies. Such serves as a precursor to well-established methods in ...